Histone deacetylase inhibitors for the treatment of cancer stem cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389030%3A_____%2F16%3A00469858" target="_blank" >RIV/61389030:_____/16:00469858 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1039/c6md00297h" target="_blank" >http://dx.doi.org/10.1039/c6md00297h</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1039/c6md00297h" target="_blank" >10.1039/c6md00297h</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Histone deacetylase inhibitors for the treatment of cancer stem cells

Popis výsledku v původním jazyce

Tiny populations of tumor cells are present in solid and hematologic malignancies and are responsible for cancer development, metastasis and limited response to therapy; these are referred to as cancer stem cells (CSCs). CSCs are resistant to standard cancer treatments and are the main cause of tumor relapse. Therefore, the development of new therapeutics to overcome the resistance of CSCs is greatly required. It is known that epigenetic histone modifications (acetylation/deacetylation) play a crucial role in cancer development through regulation of gene expression. Deacetylation of histone and non-histone proteins controls cell proliferation, metabolism and apoptosis as well as DNA repair and differentiation. Thus, histone deacetylase inhibitors (HDACis) are a promising group of anti-cancer agents, showing the ability to induce growth arrest or apoptosis in tumor cells. In this review, we summarize the current knowledge about the prospects of HDACis utilization in the treatment of CSCs.

Název v anglickém jazyce

Histone deacetylase inhibitors for the treatment of cancer stem cells

Popis výsledku anglicky

Tiny populations of tumor cells are present in solid and hematologic malignancies and are responsible for cancer development, metastasis and limited response to therapy; these are referred to as cancer stem cells (CSCs). CSCs are resistant to standard cancer treatments and are the main cause of tumor relapse. Therefore, the development of new therapeutics to overcome the resistance of CSCs is greatly required. It is known that epigenetic histone modifications (acetylation/deacetylation) play a crucial role in cancer development through regulation of gene expression. Deacetylation of histone and non-histone proteins controls cell proliferation, metabolism and apoptosis as well as DNA repair and differentiation. Thus, histone deacetylase inhibitors (HDACis) are a promising group of anti-cancer agents, showing the ability to induce growth arrest or apoptosis in tumor cells. In this review, we summarize the current knowledge about the prospects of HDACis utilization in the treatment of CSCs.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CC - Organická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/LD14128" target="_blank" >LD14128: Syntéza inhibitorů sirtuinů</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

MedChemComm

ISSN

2040-2503

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

15

Strana od-do

2217-2231

Kód UT WoS článku

000390552300002

EID výsledku v databázi Scopus

—